Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS). The ...
Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...
"Remote Learning During the Global School Lockdown: Multi-Country Lessons” and “Remote Learning During COVID-19: Lessons from Today, Principles for Tomorrow" The COVID-19 pandemic has disrupted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback